Cargando…
Improving outcomes in germ cell cancers using miRNA
Owing to advances in treatment paradigms across the last five decades, testicular cancer is now eminently curable. However, current serum tumour and imaging biomarkers lack adequate sensitivity, specificity, and predictive value. Subsequently, their utility in detecting active malignancy and informi...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252353/ https://www.ncbi.nlm.nih.gov/pubmed/34262617 http://dx.doi.org/10.1177/17588359211027826 |
_version_ | 1783717281112522752 |
---|---|
author | Conduit, Ciara Tran, Ben |
author_facet | Conduit, Ciara Tran, Ben |
author_sort | Conduit, Ciara |
collection | PubMed |
description | Owing to advances in treatment paradigms across the last five decades, testicular cancer is now eminently curable. However, current serum tumour and imaging biomarkers lack adequate sensitivity, specificity, and predictive value. Subsequently, their utility in detecting active malignancy and informing treatment decisions is minimal in a large proportion of men with testicular cancer. Micro-ribonucleic acids (miRNA), pertinently miR-371a-3p, offer a new tool, which based on early data, appears to fill many of the gaps that existing biomarkers leave. This paper reviews the evolution of the technology, potential limitations, and discusses the clinical relevance of miRNA as it moves towards the clinic. |
format | Online Article Text |
id | pubmed-8252353 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-82523532021-07-13 Improving outcomes in germ cell cancers using miRNA Conduit, Ciara Tran, Ben Ther Adv Med Oncol Review Owing to advances in treatment paradigms across the last five decades, testicular cancer is now eminently curable. However, current serum tumour and imaging biomarkers lack adequate sensitivity, specificity, and predictive value. Subsequently, their utility in detecting active malignancy and informing treatment decisions is minimal in a large proportion of men with testicular cancer. Micro-ribonucleic acids (miRNA), pertinently miR-371a-3p, offer a new tool, which based on early data, appears to fill many of the gaps that existing biomarkers leave. This paper reviews the evolution of the technology, potential limitations, and discusses the clinical relevance of miRNA as it moves towards the clinic. SAGE Publications 2021-06-30 /pmc/articles/PMC8252353/ /pubmed/34262617 http://dx.doi.org/10.1177/17588359211027826 Text en © The Author(s), 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Review Conduit, Ciara Tran, Ben Improving outcomes in germ cell cancers using miRNA |
title | Improving outcomes in germ cell cancers using miRNA |
title_full | Improving outcomes in germ cell cancers using miRNA |
title_fullStr | Improving outcomes in germ cell cancers using miRNA |
title_full_unstemmed | Improving outcomes in germ cell cancers using miRNA |
title_short | Improving outcomes in germ cell cancers using miRNA |
title_sort | improving outcomes in germ cell cancers using mirna |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252353/ https://www.ncbi.nlm.nih.gov/pubmed/34262617 http://dx.doi.org/10.1177/17588359211027826 |
work_keys_str_mv | AT conduitciara improvingoutcomesingermcellcancersusingmirna AT tranben improvingoutcomesingermcellcancersusingmirna |